Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Biohaven securities is from March 24, 2023, to May 14, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 12, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Allegations Against Biohaven - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that the overstated prospects were likely to negatively impact Biohaven's business and financial condition once revealed [4] - Investors are said to have suffered damages when the true details about the company's statements became public [4]

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a s ...

智通财经APP获悉，此前，美国食品药品监督管理局(FDA)取消了原计划就Biohaven(BHVN.US)核心药 物troriluzole上市申请召开的咨询委员会(AdCom)会议，该股美股周五盘前大幅上涨，截至发稿，该股上 涨12.3%。 在周五提交给美国证券交易委员会(SEC)的文件中，Biohaven指出，FDA已于8月21日通知该审评不再需 要召开咨询委员会会议。 Biohaven是Biohaven Pharmaceutical的分拆企业，2022年，辉瑞(PFE.US)收购了主营偏头痛药物的 Biohaven Pharmaceutical之后，Biohaven作为独立实体被拆分出来。该公司仍预计，美国食品药品监督 管理局(FDA)将在2025年第四季度对其递交的新药上市申请(NDA)做出审批决定。 今年年初，这家总部位于康涅狄格州纽黑文的生物科技公司针对脊髓小脑共济失调(一类罕见神经退行 性疾病)的troriluzole新药申请(NDA)获得了FDA的优先审评资格。 5月，FDA神经科学办公室延长了审评周期，以评估该公司为回应机构要求而提交的补充材料，并决定 召开咨询委员会会议讨论该新药申请。 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit pertains to Biohaven Ltd. securities purchased between March 24, 2023, and May 14, 2025, with a lead plaintiff deadline set for September 12, 2025 [1][2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [3] Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that these misrepresentations likely had a significant negative impact on Biohaven's business and financial condition once the truth was revealed [4]

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=162515&from=3 DEADLINE: September 12, 2025 Share ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit related to misleading statements made by the company during the class period from March 24, 2023, to May 14, 2025 [1] - Allegations include overstated regulatory prospects for the product candidate troriluzole and its efficacy for treating bipolar disorder, which may negatively impact Biohaven's business and financial condition [1] - Shareholders are encouraged to register for the class action by the deadline of September 12, 2025, to potentially become lead plaintiffs and receive updates on the case [2] Company Information - Biohaven Ltd. is facing allegations of issuing materially false and misleading statements regarding its product candidates, which could lead to significant financial repercussions [1] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to the company's alleged deceitful practices [3] Next Steps for Shareholders - Shareholders who purchased shares of Biohaven during the specified class period should register to participate in the class action, with no cost or obligation involved [2] - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]

Core Viewpoint - A class action has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Action - The class action alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the eventual revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Biohaven between March 24, 2023 and May 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi is a leading nation ...

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for bipolar disorder [2]. - It is alleged that the misleading statements were likely to have a significant negative impact on Biohaven's business and financial condition once revealed [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN). Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=161660&from=3 CLASS PERIOD: March 24, 2023 to Ma ...